Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06507306 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1 study of Solid Tumor, Adult, sponsored by Kumquat Biosciences.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
20
Study locations

NCT06507306 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 100 participants, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06507306, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by Kumquat Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG Osimertinib
  • DRUG Amivantamab
  • DRUG KQB198

Study Locations (20)

Florida

  • Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona - - Orlando
  • Florida Cancer Specialists - Sarasota - Sarasota

Texas

  • MD Anderson Cancer Center - Houston
  • New Experimental Therapeutics of San Antonio - NEXT Oncology - San Antonio

Other

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" - Naples
  • Severance Hospital, Yonsei University Health System - Seoul

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Michigan

  • Henry Ford Health System - Detroit

New York

  • David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center - Long Island City

Ohio

  • The Lindner Center for Research and Education at The Christ Hospital - Cincinnati

Tennessee

  • Sarah Cannon and HCA Research Institute - Nashville

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-06-03
Est. Completion 2027-01-31
Phase Phase 1

Sponsor

Kumquat Biosciences

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06507306

The ClinicalTrials.gov registry entry for NCT06507306 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (47% lower). The listed sponsor is Kumquat Biosciences, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.

NCT06507306 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Florida, Texas, Other.

Frequently Asked Questions

What is clinical trial NCT06507306 about?

NCT06507306 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB...

What is the current status of trial NCT06507306?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-06-03. Estimated completion is 2027-01-31.

What conditions does trial NCT06507306 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT06507306?

The interventions under investigation include: Osimertinib (DRUG), Amivantamab (DRUG), KQB198 (DRUG).

Who is sponsoring clinical trial NCT06507306?

This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06507306 being conducted?

This trial has 20 study locations across Colorado, Florida, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.